CD47 and breast cancer: In this sense, there are currently several trials evaluating ZW25 in different scenarios: ZW25 in early breast cancer (NCT05035836) and for advanced breast cancer in combination with palbociclib and fulvestrant (NCT04224272), ZW25 in combination with anti-PD1 (Programmed cell death protein 1 PD-1) in gastric cancers (NCT05270889 and NCT05152147), ZW25 plus anti-CD47 in HER2+ solid tumors including HER2-overexpressing breast cancers as well as HER2-low breast cancers (NCT05027139), ZW25 in biliary tract cancer (NCT04578444, NCT04466891, and NCT05615818), among others.